96913 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used Complement proteins, e.g. anaphylatoxin, C3a, C5a
COMPOSITIONS COMPRISING FACTOR H-LIKE PROTEIN VARIANTS FOR USE IN TREATING OCULAR DISEASES
#2Enhanced adoptive cell therapy
#3CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF
#4COMPOSITIONS INCLUDING SBI ADJUVANTS AND METHODS OF USE THEREOF
#5COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#6COMPLEMENT C4D ASSAY
#7THERAPEUTIC COMPOSITIONS AND METHODS FOR AGE-RELATED MACULAR DEGENERATION
#8SYNAPSE SURGERY TOOLS AND ASSOCIATED METHODS FOR NEURAL CIRCUIT-SPECIFIC SYNAPSE ABLATION AND MODIFICATION
#9New C5a Binding Nucleic Acids
#10GENE THERAPY
#11CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS
#12MULTIVALENT PROTEINS AND SCREENING METHODS
#13COMPLEMENT-INHIBITING HYBRID PROTEIN
#14COMPOSITIONS, KITS AND METHODS FOR TREATMENT OF COMPLEMENT-RELATED DISORDERS
#15ANTI-C5 ANTIBODIES COMBINATIONS AND USES THEREOF
#16C5a binding nucleic acids
#17C3b-Binding Fusion Proteins
#18INTERLEUKIN 2 CHIMERIC CONSTRUCTS WITH TARGETING SPECIFICY TO INFLAMED TISSUES
#19MICRO-ENGINEERED MODELS OF THE HUMAN EYE AND METHODS OF USE
#20DIMERIC PROTEIN COMPLEXES AND USES THEREOF
#21C3B INACTIVATING POLYPEPTIDE
#22METHODS OF TREATING COMPLEMENT MEDIATED DISEASES WITH FUSION PROTEIN CONSTRUCTS COMPRISING ANTI-C3d ANTIBODY AND A COMPLEMENT MODULATOR
#23KIDNEY ACTIVE FUSION PROTEINS AND METHODS OF TREATMENT USING THE SAME
#24SCREENING FOR THE EFFECTS OF COMPLEMENT PROTEIN CHANGES
#25COMPOUNDS FOR IMMUNOMODULATION
#26Properdin binding protein and use thereof
#27COMPOUNDS FOR IMMUNOMODULATION
#28COMPOSITIONS INCLUDING SBI ADJUVANTS AND METHODS OF USE THEREOF
#29HUMANIZED ANTI-C5 ANTIBODIES AND FACTOR H FUSION PROTEINS AND USES THEREOF
#30CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF
#31BINDING PROTEINS FOR COMPLEMENT FACTOR H (CFH)
#32COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#33COMPLEMENT FACTOR D ANTAGONIST ANTIBODIES AND CONJUGATES THEREOF
#34BIOLOGICAL MACROMOLECULAR TARGET-SPECIFIC COMPLEMENT INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
#35COMPLEMENT FACTOR BASED AFFINITY CHROMATOGRAPHY
#36Compositions and Methods for Adjuvanted Vaccines
#37Chimeric inhibitor molecules of complement activation
#38INHIBITORS OF COMPLEMENT FACTOR C3 AND THEIR MEDICAL USES
#39GENE THERAPY
#40POLYNUCLEOTIDE
#41FACTOR B INHIBITORS AND USES THEREOF
#42ANTI-C5A ANTIBODIES
#43Multifunctional Heteromultimeric Constructs
#44CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS
#45Chromatographic methods for purification of proteins from plasma
#46CELL-PENETRATING COMPSTATIN ANALOGS AND USES THEREOF
#47METHODS FOR TREATING PATIENTS HAVING CFH MUTATIONS WITH CFH-ENCODING VECTORS
#48METHODS FOR TREATING PATIENTS HAVING CFH MUTATIONS WITH RECOMBINANT CFH PROTEINS
#49Compositions including SBI adjuvants and methods of use thereof
#50Anti-C5 antibody combinations and uses thereof
#51C3 FUSION PROTEIN AND METHODS OF MAKING AND USING THEREOF
#52MEMBRANE ATTACK COMPLEXES AND USES THEREOF
#53C3D CELLULAR AND ACELLULAR VACCINES FOR THE PREVENTION AND TREATMENT OF CANCER
#54Modular Therapeutics for the Treatment of Inflammatory Diseases and Cancer
#55BI-FUNCTIONAL HUMANIZED ANTI-C5 ANTIBODIES AND FACTOR H FUSION PROTEINS AND USES THEREOF
#56FACTOR H VECTORS AND USES THEREOF
#57HUMANIZED C5 ANIMALS
#58C1q and HMGB1 fusion proteins and uses thereof
#59COMPOSITIONS AND METHODS RELATING TO C5L2
#60CODON-OPTIMISED COMPLEMENT FACTOR I
#61NON-HUMAN ANIMALS EXPRESSING HUMANIZED C1Q COMPLEX
#62FUSION PROTEINS AND METHODS OF TREATING COMPLEMENT DYSREGULATION USING THE SAME
#63PROTEINS WITH DIAGNOSTIC AND THERAPEUTIC USES
#64METHODS AND COMPOSITIONS TO INDUCE OR SUPPRESS IMMUNE RESPONSES THROUGH THE USE OF MEMBRANE BOUND COMPLEMENT SPLIT PRODUCTS
#65COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION AND OTHER DISEASES
#66COMPLEMENT INHIBITORS AND USES THEREOF
#67SYNTHESIS AND STRUCTURE OF HIGH POTENCY RNA THERAPEUTICS
#68Methods of treating complement mediated diseases with fusion protein constructs comprising anti-C3d antibody and a complement modulator
#69Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
#70COMPLEMENT C4D ASSAY
#71SOLUBLE COMPLEMENT RECEPTOR TYPE I VARIANTS AND USES THEREOF
#72Cell-penetrating compstatin analogs and uses thereof
#73COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION
#74COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#75COMPOSITION AND METHOD FOR TREATING COMPLEMENT-MEDIATED DISEASE
#76C5a binding nucleic acids
#77Factor B and C2 protein point mutants, a method for enhancing the activity of anti-cancer antibodies, the pharmaceutical composition and the use of mutants
#78C3 fusion protein and methods of making and using thereof
#79Micro-engineered models of the human eye and methods of use
#80Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
#81PROTEINS WITH DIAGNOSTIC AND THERAPEUTIC USES
#82Fusion protein constructs comprising anti-C3d antibody and factor H
#83Chimeric inhibitor molecules of complement activation
#84Enhanced adoptive cell therapy
#85Genetically modified non-human animals and methods relating to complement dependent cytotoxicity
#86Complement factor B analogs and their uses
#87Polypeptides for inhibiting complement activation
#88METHODS AND COMPOSITIONS TO ENHANCE THE IMMUNOGENICITY OF TUMORS
#89Anti-C5A antibodies
#90Fusion protein constructs comprising anti-C3d antibody and CR1 polypeptide
#91HYDROCHLORIDE SALTS OF C5A RECEPTOR AGONIST PEPTIDES
#92Methods and reagents for treatment of age-related macular degeneration
#93C4BP-based compounds for treating immunological diseases
#94COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#95Humanized C5 animals
#96RECOMBINANT MATURE COMPLEMENT FACTOR I
#97Complement factor based affinity chromatography
#98Multifunctional heteromultimeric constructs
#99C3A receptor agonists for use against ischemic brain injury, stroke, traumatic brain injury, spinal cord injury and neurodegenerative disorders
#100Complement factor B analogs and their uses
#101C5 IMMUNIZATION FOR AUTOLOGOUS ANTI-C5 ANTIBODY PRODUCTION
#102Polypeptides for inhibiting complement activation
#103Gene Therapy
#104Cell-penetrating compstatin analogs and uses thereof
#105ASSAY AND METHOD FOR DETERMINING CDC ELICITING ANTIBODIES
#106Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
#107Inhibitors of C5A for the treatment of viral pneumonia
#108Complement inhibitors and uses thereof
#109COMPOSITIONS AND METHODS RELATING TO C5L2
#110Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
#111Anti-C5 antibody combinations and uses thereof
#112Composition and method for treating complement-mediated disease
#113C1q and HMGB1 fusion proteins and uses thereof
#114C3D cellular and acellular vaccines for the prevention and treatment of cancer
#115Non-human animals expressing humanized C1Q complex
#116ANTI-ANTITHROMBIN SINGLE-DOMAIN ANTIBODIES AND POLYPEPTIDES COMPRISING THEREOF
#117Proteins with diagnostic and therapeutic uses
#118Nitrile hydratase
#119Recombinant complement Factor H-immunoglobulin fusion protein with complement regulatory activity, and preparation method therefor and use thereof
#120Antibody targeting cell surface deposited complement protein C3d and use thereof
#121METHODS AND COMPOSITIONS FOR DETECTING AND TREATING SCHIZOPHRENIA
#122Potent Compstatin Analogs
#123Synthesis and structure of high potency RNA therapeutics
#124Modulators of complement function
#125Collagenase-derived peptides promote tissue regeneration and wound healing
#126Complement factor D antagonist antibodies and conjugates thereof
#127Humanized C3 animals
#128Protein inhibitors to complement and VEGF pathways and methods of use thereof
#129Factor H-Fc immunotheraphy
#130Nitrile hydratase
#131Chimeric inhibitor molecules of complement activation
#132Complement split product C4d for the treatment of inflammatory conditions
#133Humanized model of kidney and liver disorders
#134C5a binding nucleic acids
#135Genetically modified non-human animals and methods relating to complement dependent cytotoxicity
#136COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#137Chromatographic methods for purification of proteins from plasma
#138COMPSTATIN ANALOGS WITH IMPROVED ACTIVITY
#139POTENT AND HIGHLY SOLUBLE PEGYLATED COMPSTATIN PEPTIDES
#140Recombinant factor H and variants and conjugates thereof
#141MASP isoforms as inhibitors of complement activation
#142Humanized C5 animals
#143POTENT COMPSTATIN ANALOGS
#144RECOMBINANT PROTEINS HAVING FACTOR H ACTIVITY
#145Chimeric inhibitor molecules of complement activation
#146Enhanced adoptive cell therapy
#147Inhibitors of C5a for the treatment of viral pneumonia
#148Complement factor B analogs and their uses
#149Protein biomarkers for immune assessment and prediction of transplant rejection
#150Antibody targeting cell surface deposited complement protein C3d and use thereof
#151Proteins with diagnostic and therapeutic uses
#152Cell-penetrating compstatin analogs and uses thereof
#153Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
#154Supplying treated exhaust gases for effecting growth of phototrophic biomass
#155Nitrile hydratase
#156Complement factor B analogs and their uses
#157Nitrile hydratase
#158Method for preparing C1q recombinant protein
#159Compstatin analogs
#160Humanized C3 animals
#161BIOACTIVE PEPTIDES AND METHODS OF USING SAME
#162Enhanced adoptive cell therapy
#163Chimeric inhibitor molecules of complement activation
#164Complement split product C4d for the treatment of inflammatory conditions
#165Method of inhibiting C5a
#166Regulator of complement activation and uses thereof
#167Method for evaluating ischemic heart disease by assaying complement factor H or D
#168C1q peptides and uses thereof
#169BIOMARKERS FOR BREAST CANCER
#170Protein inhibitors to complement and VEGF pathways and methods of use thereof
#171METHOD FOR PURIFICATION OF COMPLEMENT FACTOR H
#172Fusion protein for enhancing immunogenicity of bacterial antigen/immunogen
#173C5a binding nucleic acids
#174Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
#175Compositions and methods for immunomodulation
#176Complement factor B analogs and their uses
#177Nitrile hydratase
#178Compositions having antiangiogenic activity and uses thereof
#179Method for screening substance relating to endoplasmic reticulum stress participating in onset of diabetes
#180Manufacture of factor H (FH) and FH-derivatives from plasma
#181Biomarker and uses thereof in diagnosis, treatment of autism
#182Recombinant codon optimised factor H
#183Chimeric inhibitor molecules of complement activation
#184Methods for inhibiting C5a with C5a peptides coupled or fused to a carrier protein
#185Complement receptor 2 (CR2) targeting groups
#186Antibodies to the C3d fragment of complement component 3
#187Manufacture of factor H (FH) and FH-derivatives from plasma
#188ANTIBODIES TO THE C3d FRAGMENT OF COMPLEMENT COMPONENT 3
#189CYCLIC AGONISTS AND ANTAGONISTS OF C5A RECEPTORS AND G PROTEIN-COUPLED RECEPTORS
#190Cyclic Peptides As G-Protein Coupled Receptor Antagonists
#191MASP ISOFORMS AS INHIBITORS OF COMPLEMENT ACTIVATION
#192SUPPLYING TREATED EXHAUST GASES FOR EFFECTING GROWTH OF PHOTOTROPHIC BIOMASS
#193Compositions having antiangiogenic activity and uses thereof
#194Expression and application of recombinant FAEES in algae as a novel method to produce biodiesel in vivo
#195TRANS-MEMBRANE-ANTIBODY INDUCED INHIBITION OF APOPTOSIS
#196BIMER OR AN OLIGOMER OF A DIMER, TRIMER, QUADROMER OR PENTAMER OF RECOMBINANT FUSION PROTEINS
#197Potent compstatin analogs
#198Compstatin analogs with improved activity
#199CYSTINE KNOT MOLECULES
#200Novel Regulators of the Innate Immune System
#201High Affinity Nucleic Acid Ligands of Complement System Proteins
#202Methods of using multimeric complexes of antigens and an adjuvant
#203Bioactive peptides and methods of using same
#204FIBROMYALGIA TEST METHOD
#205COMPLEMENT FACTOR H-DERIVED SHORT CONSENSUS REPEAT-ANTIBODY CONSTRUCTS
#206Structure of compstatin-C3 complex and use for rational drug design
#207Manufacture of factor H (FH) and FH-derivatives from plasma
#208METHODS FOR PREVENTION AND TREATMENT OF INFECTIONS WITH SUPRAPHYSIOLOGICAL DOSES OF MANNAN-BINDING LECTIN (MBL) AND FICOLIN-MBL FUSION PROTEINS
#209CYCLIC PEPTIDES AS G-PROTEIN COUPLED RECEPTOR ANTAGONISTS
#210Cystine knot molecules
#211LABELED PEPTIDE HAVING ACTIVITY OF BINDING TO IMMUNOGLOBULIN AND/OR IMMUNOGLOBULIN COMPLEX AND METHOD OF DETECTING OR ASSAYING IMMUNOGLOBULIN BY USING THE PEPTIDE
#212CR-2 binding peptide P28 as molecular adjuvant for DNA vaccines
#213Compstatin analogs with improved activity
#214HUMAN COMPLEMENT C3 DERIVATIVES WITH COBRA VENOM FACTOR-LIKE FUNCTION
#215Peptide capable of binding to immunoglobulin
#216Compositions Having Antiangiogenic Activity and Uses Thereof
#217TREATMENT OF DISEASES CHARACTERIZED BY INFLAMMATION
#218Complement factor H protein as a biomarker of Parkinson's disease
#219TRANS-MEMBRANE-ANTIBODY INDUCED INHIBITION OF APOPTOSIS
#220Complement depletion using recombinant human C-3 derivatives
#221Diagnosis and Treatment of Age-Related Macular Degeneration
#222Therapeutic compositions for age-related macular degeneration comprising a complement factor H with isoleucine at residue 62 and tyrosine at residue 402
#223CYCLIC AGONISTS AND ANTAGONISTS OF C5a RECEPTORS AND G PROTEIN-COUPLED RECEPTORS
#224Peptide-complement conjugates
#225Complement factor H for diagnosis of age-related macular degeneration
#226Multimeric complexes of antigens and an adjuvant
#227Complement C3A Derived Peptides and Uses Thereof
#228BIMER OR AN OLIGOMER OF A DIMER, TRIMER, QUATROMER OR PENTAMER OF RECOMBINANT FUSION PROTEINS
#229Human complement C3 derivates with cobra venom factor-like function
#230Product Comprising a C4bp Core Protein and a monomeric Antigen, and Its Use
#231Compositions, methods, and kits for assaying complement activation
#232Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
#233METHODS AND MATERIALS FOR TREATING INFLAMMATORY CONDITIONS
#234Immuno-Adsorbers For Treatment of Inflammations
#235Compositions, kits, and methods for identification, assessment, prevention, and therapy of endometriosis
#236Human complement C3 derivates with cobra venom factor-like function
#237Potent compstatin analogs
#238C5a Receptor Antagonist
#239Modified truncated complement system regulators
#240Transgenic mouse comprising a polynucleotide encoding human or humanized C5aR and methods of production and use
#241TNF-like secreted protein
#242Multimeric complexes of antigens and adjuvants
#243Isolated INSP 163 protein
#244Compositions and methods for generating an immune response
#245Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
#246Methods for treatment of age-related macular degeneration
#247Complement C3 precursor biopolymer markers indicative of insulin resistance
#248Immunoprotective influenza antigen and its use in vaccination
#249Methods for treatment of pain
#250Cyclic peptides as G-protein-coupled receptor antagonists
#251Complement C3 precursor biopolymer markers indicative of insulin resistance
#252Complement inhibitor
#253Cyclic agonists and antagonists of C5a receptors and G protein-coupled receptors
#254Compositions and methods for the threatment of sepsis
#255High affinity nucleic acid ligands of complement system proteins
#256Methods and compositions for modulating C5-a-mediated inflammatory responses
#257Muteins of C5a anaphylatoxin and methods of inhibiting C5a
#258DNA expression vectors and methods of use
#259Cyclic molecular framework and derivatives thereof
#260Adipocyte complement related protein homolog zacrp3
#261Adipocyte complement related protein zacrp13
#262Cat immunisation vectors
#263Compositions, kits, and methods for identification, assessment, prevention, and therapy of endometriosis
#264Peptides that inhibit complement activation
#265Peptides that promote complement activation
#266Complement depletion using recombinant human C3-derivatives
#267Antibacterial therapy with bacteriophage genotypically modified to delay inactivation by the host defense system
#268Use of complement protein C3 and its derivatives in enhancing mammalian embryo development
#269Method for detecting alzheimer's disease and differentiating alzheimer's disease from other demential diseases associated peptides and use thereof
#270Mannose binding lectin and uses thereof
#271Trans-membrane-antibody induced inhibition of apoptosis
#272Compositions and methods for enhancing immune responses mediated by antigen-presenting cells